FDA Warns of Counterfeit Ozempic

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 22, 2023.

By Dennis Thompson HealthDay Reporter

FRIDAY, Dec. 22, 2023 -- The U.S. Food and Drug Administration has uncovered counterfeit Ozempic shots in the legitimate U.S. drug supply chain, and is warning patients to be on their guard.

The FDA said Thursday that it has seized thousands of counterfeit doses of Ozempic, the weight-loss drug manufactured by Novo Nordisk, but warned that more might still be available for purchase.

Patients, practitioners and pharmacies are specifically warned not to sell or use Ozempic 1-milligram (mg) injections labeled with lot number NAR0074 and serial number 430834149057, the FDA said.

People in possession of Ozempic doses meeting that description can report the counterfeit product directly to the FDA’s Office of Criminal Investigations, the agency said.

The agency and the drugmaker are testing the seized products, but don’t yet have any information yet about the fake drugs’ identity, quality or safety.

Five people have gotten sick from injections of the counterfeit Ozempic, but no cases have been serious, the FDA said.

The sickened patients all suffered side effects consistent with legitimate Ozempic, like nausea, vomiting, diarrhea, abdominal pain and constipation.

The rest of the Ozempic injection package is also counterfeit, including the needles, the injection pen label, the carton and the accompanying doctor and patient information, the FDA said.

Because the needles are counterfeit, their sterility can’t be guaranteed and an injection presents an infection risk to anyone using the fake product, the FDA said.

In a news release issued Thursday, Novo Nordisk encouraged patients to only buy Ozempic through pharmacies.

“If a prescription is filled via a major retailer who uses our authorized distributors, Novo Nordisk believes the risk of receiving counterfeit product is minimized,” the company said.

The FDA seizures took place in warehouses outside the company’s authorized supply chain, Novo Nordisk told NBC News.

Sources

  • U.S. Food and Drug Administration, news release, Dec. 21, 2023
  • Novo Nordisk, news release, Dec. 21, 2023
  • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords